Basel, Switzerland and Vacaville, US, 1 October 2024 – Lonza, one of the world’s largest healthcare development and manufacturing organizations, today announced it has completed its acquisition of the ...

(RTTNews) - Swiss drug major Roche Group (RHHBY), at its Pharma Day 2024, said it expects sales momentum to continue into 2025, with strong growth by both divisions of Pharma and Diagnostics. The ...

Roche is planning to launch 13 medicines by the end of the decade and cut research costs for new drugs by a fifth, according to a strategy update on Monday.

Neporrhoids certainly has one of the more interesting show starts of the Fringe. Roche kneels in front of a keyboard on the ...

Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) ...

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

Roche’s current pharmaceutical portfolio will deliver growth through at least 2027, the company said. Schinecker has already ...

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus ...

New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a ...

PiaSky's approval by the MHRA earlier this year was based on the COMMODORE study, which showed that the drug was equivalent ...

Chinese Vice Premier He Lifeng met with Severin Schwan chairman of the Board of Directors of Roche Group in Beijing on Friday evening He also a me ...

The TAGS technology has PCR testing capabilities on high-throughput systems such as the cobas 5800, 6800, and 8800 models.